Royalty Pharma introduced a 13% hike in its quarterly dividend to $0.17 per share from $0.15.
Royalty Pharma (RPRX) stated that the brand new quarterly dividend can be paid by Mar. 15 to shareholders of file as of Feb. 19. Its annual dividend of $0.68 per share now displays a dividend yield of 1.3%.
Earlier on Dec. 7, Royalty Pharma introduced that it’s going to purchase a royalty curiosity in Orladeyo remedy and BCX9930 from BioCryst Prescription drugs. Royalty Pharma, together with Athyrium Capital Administration, will present about $325 million in funding for BioCryst to assist the launch of Orladeyo remedy to deal with hereditary angioedema dysfunction and the event of BCX9930, which is an oral Issue D inhibitor. (See RPRX stock analysis on TipRanks)
In the meantime, on Nov. 9, UBS analyst Navin Jacob upgraded Royalty Pharma inventory from Maintain to Purchase. Jacob stated, “Inventive transactions, such because the BHVN [Biohaven Pharmaceutical Holding Company Ltd.] financing and NPV [net present value] constructive Cystic Fibrosis deal, will increase the probability of low double digit IRR [internal rate of return] on new investments.”
The analyst added, “RPRX’s low value of debt (~2%) & 0% tax charge creates a possibility to spend money on royalty streams and in biotech firms at extra favorable phrases than opponents.”
Nonetheless, Jacob lowered the price target to $51 (0.53% draw back potential) from $52. Shares have gained 16.1% because it was listed on the NASDAQ on June 16, 2020.